CSTL Stock Overview
A molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Castle Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.85 |
| 52 Week High | US$30.46 |
| 52 Week Low | US$12.07 |
| Beta | 0.93 |
| 11 Month Change | 36.99% |
| 3 Month Change | 17.61% |
| 1 Year Change | 53.62% |
| 33 Year Change | -61.30% |
| 5 Year Change | 3.33% |
| Change since IPO | 34.81% |
Recent News & Updates
Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Recent updates
Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?
Aug 05Shareholder Returns
| CSTL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.2% | 1.2% | 0.1% |
| 1Y | 53.6% | 13.9% | 24.9% |
Return vs Industry: CSTL exceeded the US Healthcare industry which returned 14.1% over the past year.
Return vs Market: CSTL exceeded the US Market which returned 25.9% over the past year.
Price Volatility
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 10.1% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CSTL's share price has been volatile over the past 3 months.
Volatility Over Time: CSTL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 703 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
Castle Biosciences, Inc. Fundamentals Summary
| CSTL fundamental statistics | |
|---|---|
| Market cap | US$820.18m |
| Earnings (TTM) | -US$3.10m |
| Revenue (TTM) | US$287.59m |
2.8x
P/S Ratio-258.2x
P/E RatioIs CSTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSTL income statement (TTM) | |
|---|---|
| Revenue | US$287.59m |
| Cost of Revenue | US$52.16m |
| Gross Profit | US$235.43m |
| Other Expenses | US$238.53m |
| Earnings | -US$3.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 81.86% |
| Net Profit Margin | -1.08% |
| Debt/Equity Ratio | 2.4% |
How did CSTL perform over the long term?
See historical performance and comparison